Literature DB >> 29682983

Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease.

Kristen M Walters1, Jeremy D Waldram1, Katharine M Woessner1, Andrew A White1.   

Abstract

Background Aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad or aspirin (ASA)-intolerant asthma, affects 7% of asthmatics and has a higher prevalence in those with chronic rhinosinusitis and concomitant nasal polyposis. ASA desensitization with daily ASA therapy is a uniquely beneficial treatment for this disease entity and has been shown to have a significant impact on symptom scores, polyp disease, and need for systemic corticosteroids. However, no long-term studies have demonstrated whether or not ASA therapy remains safe and beneficial for these patients beyond 5-10 years. Objective This study was designed to determine the clinical course of AERD patients desensitized between 1995 and 2010. Methods A 20-question survey was distributed to patients who successfully completed ASA desensitization between January 1995 and April 2010. The questions were designed to assess ASA safety and longitudinal effects of ASA therapy in AERD. Results Of the 285 patients contacted, 92 (32%) completed the questionnaire. Average length of follow-up was 15 years. Of survey responders, 35 patients had discontinued ASA therapy. Although adverse reactions occurred, many also discontinued due to lack of efficacy or need for surgery. For those remaining on ASA (62%), significant improvement in sense of smell, asthma, sinus, and allergic rhinitis scores were noted ( P ≤ .001). The majority of ASA patients (68%) had a positive response to treatment and did not require further sinus surgery. However, ASA therapy did not delay the time to next sinus/polyp surgery ( P = .27) or reduce total number of sinus surgeries ( P = .56) compared to those who stopped treatment. Nearly 85% of AERD patients on ASA therapy found it to be helpful in improving airway disease and quality of life. Conclusion Aspirin desensitization followed by daily maintenance ASA therapy appears to be safe and effective even after 10+ years of continuous use.

Entities:  

Keywords:  NSAID intolerance; Samter’s triad; aspirin desensitization; aspirin side effects; aspirin-exacerbated respiratory disease; aspirin-intolerant asthma; chronic rhinosinusitis; nasal polyps; questionnaire; safety; survey

Mesh:

Substances:

Year:  2018        PMID: 29682983     DOI: 10.1177/1945892418770260

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  13 in total

1.  Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease.

Authors:  Auddie M Sweis; Tran B Locke; Kevin I Ig-Izevbekhai; Theodore C Lin; Ankur Kumar; Jennifer E Douglas; Andrew M Corr; Alyssa M Civantos; Siddhant H Tripathi; David W Kennedy; Michael A Kohanski; James N Palmer; Nithin D Adappa; John V Bosso
Journal:  Allergy Asthma Proc       Date:  2021-03-01       Impact factor: 2.587

Review 2.  New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease.

Authors:  Esha Sehanobish; Mohammad Asad; Elina Jerschow
Journal:  Curr Opin Allergy Clin Immunol       Date:  2022-02-01

3.  Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.

Authors:  Hannah Wangberg; Samantha R Spierling Bagsic; Lilliana Osuna; Andrew A White
Journal:  J Allergy Clin Immunol Pract       Date:  2021-09-28

4.  Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: Efficacy, tolerability, and patient experience.

Authors:  Jyotsna Mullur; Camille M Steger; Deborah Gakpo; Jillian C Bensko; Rie Maurer; Tanya M Laidlaw; Kathleen M Buchheit
Journal:  Ann Allergy Asthma Immunol       Date:  2022-02-05       Impact factor: 6.248

5.  Endoscopic sinus surgery improves aspirin treatment response in aspirin-exacerbated respiratory disease patients.

Authors:  Sharan J Shah; Waleed M Abuzeid; Anusha Ponduri; Teresa Pelletier; Zhen Ren; Taha Keskin; Gigia Roizen; David Rosenstreich; Denisa Ferastraoaru; Elina Jerschow
Journal:  Int Forum Allergy Rhinol       Date:  2019-09-30       Impact factor: 3.858

Review 6.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

7.  Regular Treatment With Aspirin 300 mg/day After Desensitization in Patients With N-ERD: 12-Year Results.

Authors:  Saltuk Buğra Kaya; Mehmet Erdem Çakmak; Ebru Damadoğlu; Gül Karakaya; Ali Fuat Kalyoncu
Journal:  Turk Thorac J       Date:  2021-09

8.  Aspirin desensitization in NSAID-exacerbated respiratory disease and its outcomes in the clinical course of asthma: A systematic review of the literature and meta-analysis.

Authors:  Isabel Eraso; Saveria Sangiovanni; Eliana I Morales; Liliana Fernández-Trujillo
Journal:  PLoS One       Date:  2021-03-26       Impact factor: 3.240

Review 9.  Update on the Management of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity.

Authors:  Wan Yin Winnie Yeung; Hae Sim Park
Journal:  Yonsei Med J       Date:  2020-01       Impact factor: 2.759

Review 10.  Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.

Authors:  Esha Sehanobish; Mohammad Asad; Mali Barbi; Steven A Porcelli; Elina Jerschow
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.